icon-folder.gif   Conference Reports for NATAP  
The Liver Meeting
Boston MA
November 2016
Back grey_arrow_rt.gif
Predictors of Improvement in Glomerular Filtration Rate Among Patients Treated With Ombitasvir/Paritaprevir/r and Dasabuvir With or Without Ribavirin
  "BL proteinuria, BL BMI, non-black race, and a history of diabetes were BL predictors associated with an increase of ≥10 mL/min/1.73 m2 eGFR at EOT among patients treated with OBV/PTV/r + DSV ± RBV"   


Reported by Jules Levin
AASLD 2016 Nov 11-15 Boston, MA
(HepDart) Treatment With Ombitasvir/Paritaprevir/r Plus Dasabuvir With Ribavirin Was Not Associated With Changes in Renal Function: An Analysis of 1211 Patients Enrolled in Four Phase 2 and 3 Trials (12/14/15)
(HepDart) Efficacy and Safety of Ombitasvir/Paritaprevir/r + Dasabuvir ± Ribavirin According to Baseline Renal Function: Analysis of 2005 Patients Enrolled in Six Phase 3 Trials (12/14/15)
D Bernstein1, A Tran2, P Martin3, K Kowdley4, M Bourlière5, MS Sulkowski6, PJ Pockros7, L Larsen8, D Shuster8, DE Cohen8, B Renjifo8, IM Jacobson9
1Department of Medicine, Hofstra Northwell School of Medicine, Manhasset, New York, United States; 2University Hospital of Nice, Digestive Centre, Nice, F-06202, Cedex 3, France; 3Division of Hepatology, School of Medicine, University of Miami, Miami, Florida, United States;
4Swedish Medical Center, Seatt le, Washington, United States; 5Hôpital Saint Joseph, Marseilles, France; 6Viral Hepatitis Center, Johns Hopkins University, Baltimore, Maryland, United States; 7Scripps Clinic and Scripps Translational Science Institute, La Jolla, California, United States;
8AbbVie Inc., North Chicago, Illinois, United States; 9Mount Sinai Beth Israel, New York, New York, United States